Earlier this week I blogged about Eli Lilly's "Coming Soon" banner ad I spotted in the online edition of "The New England Journal of Medicine." It's designed to generate buzz about the company's crucial new bloodthinner that could win Food and Drug Administration approval this month.    Read More

Dendreonians, the wait is over. Dendreon had the second-to-last time slot at the BioCentury/Thomson Reuters biotech investment conference this afternoon.    Read More

One of the biggest biotech success stories is among the companies featured in the afternoon sessions here at the BioCentury/Thomson Reuters investment conference.    Read More

Of the 36 companies presenting here at the BioCentury/Thomson Reuters biotech conference, investors are probably most interested in the update from Amylin Pharmaceuticals.    Read More

After Medivation, I moved onto the Orexigen presentation. It's a company I profiled at when it had data on one of its fat-fighting drugs at last year's diabetes conference, so I wanted to check up on its progress.    Read More

A little more than 24 hours after announcing its big, lucrative Alzheimer's drug partnership with Pfizer, Medivation had the lead-off position (I wonder if they told organizers they'd be a newsmaker) at today's BioCentury/Thomson Reuters biotech investment conference in New York City.    Read More

Today I will be attending and blogging from the 15th Annual Newsmakers in the Biotech Industry conference which is put on by BioCentury Publications and Thomson Reuters. Three dozen biotechs will be making presentations and then doing hour-long q and a's during breakout sessions.    Read More

In late July at a big scientific conference in Chicago, I reported on new, positive data on Medivation's experimental Alzheimer's drug Dimebon (dim-uh-bahn).    Read More

While I was on the "New England Journal of Medicine" Web site yesterday preparing my reports for today about the embargoed articles, I noticed a banner ad at the top of the homepage from Eli Lilly saying something along the lines of, "Coming Soon: Effient (Prasugrel)."    Read More

This won't be much of an end-of-summer holiday weekend for the folks at Merck and Schering-Plough. That's because early Tuesday morning (5am ET) the detailed results of the so-called SEAS study will be presented at a scientific conference in Germany. This is the test of MRK and SGP's cholesterol drug Vytorin, which showed a higher incidence of cancer among the patients taking the pill.   Read More